People · Operator
Named in public records as an officer, director or promoter · active 2010–2021 · Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Via Science, Inc. | — | Other Technology | Series B | $51.2M | $174.2M | 2019 |
| Gene Network Sciences, Inc. | — | Other Technology | Pre-Seed | $450K | $19.1M | 2010 |
Duncan McFarland at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Duncan McFarland on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Adam Jackson | 1 | 7 |
| Michael Gilman | 1 | 6 |
| Kasper Sage | 1 | 4 |
| COLIN GOUNDEN | 1 | 4 |
| IYA KHALIL | 1 | 3 |
| THOMAS PAUL | 1 | 3 |
| COLIN HILL | 1 | 2 |
| Danny Cotter | 1 | 2 |
| THOMAS NEYARAPALLY | 1 | 2 |
| J. WESTON CASHMAN | 1 | 1 |
| Alan Parnass | 1 | 1 |
| Katherine Ravanis | 1 | 1 |
| Jeremy Taylor | 1 | 1 |
| Kristen Merrill | 1 | 1 |
| Chris Daher | 1 | 1 |
| Kate Ravanis | 1 | 1 |
| F. RAYMOND SALEMME | 1 | 1 |
| ALAN BILOSKI | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.